CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
After the solid Q1 results announcement this morning amid a challenging operating environment, we retain our target at $100, based on 24.8x our 2027 EPS estimate, a discount to its five-year historical forward P/E average of 27.5x. We lower our 2026 EPS view to $3.40 from $3.49 as we adjust our top- and bottom-line forecasts to take into account a softer outlook in the Electrophysiology, Watchman, and Urology businesses. We maintain our 2027 EPS estimate at $4.04. We continue to view the large $14.5 billion pending acquisition of Penumbra (a leading thrombectomy firm focused on innovative technologies to treat challenging medical conditions), which is expected to close in the second half of 2026, as strategically compelling for BSX and potentially key to accelerating its growth. Despite near-term challenges (supply chain disruptions, increased competition), we remain confident in the company's long-term growth prospects, supported by a strong product pipeline and strategic investments.